QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
April 24, 2024 16:05 ET
|
QIAGEN N.V.
Venlo, the Netherlands, April 24, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for...
QIAGEN erweitert Tuberkulose-Portfolio: Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen
April 24, 2024 16:05 ET
|
QIAGEN N.V.
VENLO, Niederlande, April 24, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung des QIAseq xHYB Mycobacterium tuberculosis Panel zu...
Amplify Energy Schedules First Quarter 2024 Earnings Release and Conference Call
April 24, 2024 16:05 ET
|
Amplify Energy Corp.
HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that it will report first quarter 2024 financial and operating results...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
Churchill Downs Incorporated Reports 2024 First Quarter Results
April 24, 2024 16:02 ET
|
Churchill Downs Incorporated
LOUISVILLE, Ky., April 24, 2024 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company", "CDI", "we") today reported business results for the first quarter ended March 31,...
Finward Bancorp Announces Earnings for the Quarter Ended March 31, 2024
April 24, 2024 16:02 ET
|
Finward Bancorp
MUNSTER, Ind., April 24, 2024 (GLOBE NEWSWIRE) -- Finward Bancorp (Nasdaq: FNWD) (the “Bancorp”), the holding company for Peoples Bank (the “Bank”), today announced that net income available to...
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 24, 2024 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Great Lakes Announces New $150,000,000 Second-Lien Financing Agreement
April 24, 2024 16:01 ET
|
Great Lakes Dredge & Dock Corporation
HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the largest provider of dredging services in the United...
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:01 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...